1. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition 
C. Allison Stewart, Lauren Averett Byers 
Cancer Cell 
Volume 28, Issue 1, Pages 4-6 (July 2015)
DOI: /j.ccell
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Figure 1
Proposed DNA Hypomethylation Signature to Predict SCLC Sensitivity
(A) A signature of 45 differentially methylated CpGs was associated with in vitro sensitivity to the LSD1 inhibitor GSK To test the performance of the methylation signature, patient-derived xenografts (PDXs) were scored to predict drug response. Two PDXs with positive methylation signature scores responded to GSK , whereas a PDX with a negative score was resistant.
(B) Clinical schema of proposed mechanism of GSK in a biomarker selected SCLC patient population. Following an initial treatment period with chemotherapy, treatment of stem-cell enriched residual SCLC tumor leads to further regression and disease control.
Cancer Cell  , 4-6DOI: ( /j.ccell )
Copyright © 2015 Elsevier Inc. Terms and Conditions